Human Relaxin-2 + Adrenomedullin Peptide Stack

This research stack integrates Human Relaxin-2 and Adrenomedullin, both of which play significant roles in cardiovascular health. Human Relaxin-2 is primarily recognized for its ability to induce vasodilation and modulate fibrosis, while Adrenomedullin is known for its potent vasodilatory and natriuretic effects. Studies indicate that the independent pathways activated by these peptides may work synergistically to improve vascular function and reduce cardiac stress. This dual-action approach may provide valuable insights into the treatment of cardiovascular diseases, particularly in scenarios where traditional therapies have limitations.

Human Relaxin-2, a peptide hormone with structural similarities to insulin, has garnered attention for its cardiovascular applications beyond its initial role in pregnancy. Research has highlighted its potential in managing acute heart failure, although the pivotal Phase 3 RELAX-AHF-2 trial did not meet its primary endpoints, leading to a reevaluation of its clinical development. Ongoing studies are investigating its efficacy in liver fibrosis and portal hypertension, suggesting a broader therapeutic scope. The mechanism of action involves activation of the relaxin family peptide receptor 1 (RXFP1), which engages multiple intracellular pathways, including increased nitric oxide production and matrix metalloproteinase activation, contributing to vasodilation and anti-fibrotic effects. These findings underscore the complexity of Relaxin-2's role in cardiovascular health and its potential for future research.

Adrenomedullin, a 52-amino-acid peptide, is integral to cardiovascular physiology, exhibiting significant vasodilatory and cardioprotective properties. Initially isolated from pheochromocytoma tissue, it is now recognized for its widespread expression in various systems, including the heart and kidneys. Current research is exploring its utility as a biomarker for conditions such as sepsis and heart failure, although no therapeutic applications have been approved. The peptide's mechanism involves interaction with the calcitonin receptor-like receptor complex, leading to enhanced cAMP production and subsequent vasodilatory effects. Furthermore, Adrenomedullin promotes natriuresis and exhibits anti-inflammatory and anti-fibrotic properties, positioning it as a key player in cardiovascular research. The stability of its mid-regional fragment, MR-proADM, as a biomarker illustrates the peptide's potential beyond direct therapeutic use, highlighting avenues for further investigation.